Posted by Michael Wonder on 18 Dec 2023
AnHeart Therapeutics and Innovent Announce China’s NMPA has granted taletrectinib (ROS1 inhibitor) priority review designation
18 December 2023 -AnHeart Therapeutics and Innovent Biologics today announced the Center for Drug Evaluation of China’s National Medical Products Administration has granted priority review designation for the new drug application of taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1 positive non-small-cell lung cancer who have been previously treated with ROS1 tyrosine kinase inhibitors.
The Center for Drug Evaluation accepted the new drug application in November 2023.
